--- title: "Zantac Cancer Lawsuit: Ranitidine NDMA Contamination Claims" url: https://www.masstortmarketingagency.com/blogs/zantac-cancer-lawsuit canonical: https://www.masstortmarketingagency.com/blogs/zantac-cancer-lawsuit published: 2025-12-12 modified: 2025-12-12 author: name: Tarun role: Founder, Mass Tort Agency publisher: name: Mass Tort Agency url: https://www.masstortmarketingagency.com description: | FDA withdrawal, qualifying cancers, MDL 2924 developments, Daubert rulings, and state court strategies for Zantac ranitidine litigation. Covers the NDMA contamination science (Valisure's 31,000x findings), manufacturer defendants (Sanofi, GSK, Boehringer Ingelheim, Pfizer), settlement ranges, and how to build a plaintiff portfolio. keywords: - Zantac cancer lawsuit - ranitidine NDMA contamination - MDL 2924 - Zantac Daubert ruling - qualifying cancers Zantac - FDA ranitidine withdrawal license: | Cite freely with attribution to Mass Tort Agency. Verbatim quoting permitted with citation back to the canonical URL. --- # Zantac cancer lawsuit: ranitidine NDMA contamination claims > **Quick answer.** Zantac (ranitidine) was withdrawn from the U.S. market by FDA order on April 1, 2020 after testing showed the drug degrades into NDMA, a probable human carcinogen — Valisure's June 2019 tests found over 3,000,000 nanograms per tablet under simulated storage heat, more than 31,000 times the FDA's 96 ng/day limit. Federal MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) held 70,000+ cases at its peak before a December 2022 Daubert ruling excluded plaintiffs' experts; the litigation now continues in state courts, led by California under the Kelly/Frye standard. Qualifying cancers include bladder, stomach, liver, esophageal, pancreatic, and colorectal cancer. Key stats: 15M+ annual U.S. prescription users; 70K+ MDL plaintiff cases at peak; 31,000x FDA limit exceeded in testing; 2020 FDA market withdrawal. ## Why the Zantac litigation remains a critical opportunity For decades Zantac was one of the most widely used OTC and prescription medications in the world. In 2019, independent laboratory testing revealed that ranitidine is inherently unstable and degrades into N-Nitrosodimethylamine (NDMA) — classified a probable human carcinogen by IARC and the EPA. The revelation triggered FDA warnings, voluntary recalls, and a full April 2020 market withdrawal, followed by thousands of lawsuits against manufacturers, distributors, and retailers. ## What is Zantac and how did ranitidine become a household name? Ranitidine is a histamine-2 (H2) receptor antagonist used for GERD, peptic ulcers, Zollinger-Ellison syndrome, and heartburn. FDA-approved in 1983, it became the world's best-selling drug by the late 1980s. Originally manufactured by Glaxo Holdings (now GSK), it later passed among Sanofi, Boehringer Ingelheim, and Pfizer in branded and generic forms. At its peak, roughly 15 million Americans used Zantac annually on a prescription basis alone, with millions more buying OTC; hundreds of millions of people worldwide consumed ranitidine between 1983 and 2020. ## The science behind NDMA contamination NDMA is an N-nitrosamine classified as a Group 2A probable human carcinogen by IARC, shown to cause tumors in laboratory animals in the liver, lungs, kidneys, and gastrointestinal tract; it was historically used in rocket fuel manufacturing. The FDA's acceptable daily intake limit is 96 nanograms per day. Unlike drugs recalled for NDMA as a manufacturing impurity (e.g., certain valsartan products), the ranitidine molecule itself contains both a nitrite group and a dimethylamine group — the chemical precursors of NDMA — so it generates NDMA endogenously during storage and after ingestion in the stomach's acidic environment. Valisure, an independent pharmacy and laboratory, showed in June 2019 that heating ranitidine to simulate long-term storage drove NDMA above 3,000,000 nanograms per tablet — more than 31,000 times the FDA limit. ## FDA regulatory timeline - **September 2019:** FDA initial alert on low NDMA levels in ranitidine; no stop-use recommendation yet. - **October–November 2019:** voluntary recalls by generic manufacturers; Sanofi withdrew OTC Zantac from U.S. stores in October 2019. - **April 1, 2020:** FDA requested all manufacturers withdraw all ranitidine products from the U.S. market immediately, stating: "We determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity." | Date | Action | Significance | |---|---|---| | Sept 2019 | FDA initial alert | Low NDMA levels identified | | Oct 2019 | Voluntary recalls | Sanofi pulls OTC Zantac | | Apr 2020 | Full market withdrawal | All ranitidine removed | | Dec 2022 | MDL Daubert ruling | Expert testimony excluded | ## The manufacturer defendants - **Sanofi:** manufacturer of branded OTC Zantac (Zantac 150 and Zantac 75); acquired the OTC rights from Pfizer in 2017 and marketed the drug until the 2019 recalls. - **GlaxoSmithKline (GSK):** original developer and manufacturer; plaintiffs argue GSK knew of ranitidine's chemical instability and nitrosamine-formation potential from the earliest development stages. - **Boehringer Ingelheim and Pfizer:** each manufactured or distributed Zantac during certain periods; both face inadequate-testing and failure-to-warn allegations. - Numerous generic manufacturers, pharmacies, and retailers (including CVS, Walgreens, Walmart) are also named. ## Qualifying cancers The litigation focuses on cancers linked to NDMA exposure through research, epidemiology, and the known carcinogenic mechanism: - **Bladder cancer** — among the most frequently alleged; NDMA is excreted through the urinary system, concentrating exposure in the bladder lining. - **Stomach (gastric) cancer** — ranitidine generates NDMA in the stomach's acidic environment. - **Liver cancer** — NDMA is metabolized primarily in the liver; animal studies consistently show liver tumors. - **Esophageal cancer** — GERD patients had direct drug-to-esophageal-tissue contact. - **Pancreatic cancer** — some studies associate NDMA exposure with this aggressive cancer. - **Colorectal cancer** — GI-tract transit exposes colorectal tissue to NDMA. Some plaintiffs also allege kidney, prostate, and breast cancer links, though the evidence for these is less developed than for the core six. ## MDL 2924: the federal multidistrict litigation In February 2020 the JPML consolidated all federal Zantac lawsuits as *In re: Zantac (Ranitidine) Products Liability Litigation*, MDL No. 2924, in the Southern District of Florida before Judge Robin L. Rosenberg. At its peak the MDL included over 70,000 plaintiff cases — among the largest MDLs in U.S. history. **The December 2022 Daubert ruling** excluded plaintiffs' expert testimony, finding the experts had not reliably shown that ranitidine at standard therapeutic doses caused the specific cancers. The court questioned the NDMA-exposure estimation methodology, found inadequate treatment of confounding factors, noted gaps between animal-study data and the alleged cancer types, and criticized dose-response modeling as speculative. ## State court litigation: where the case is very much alive After the federal Daubert ruling, plaintiffs pivoted to state courts, many of which use more permissive expert-admissibility standards (Frye or hybrid approaches). California — applying the Kelly/Frye general-acceptance standard — has emerged as the key jurisdiction. Cases are also pending in Delaware (where several defendants are incorporated), Illinois, New Jersey, and other states. ## Who qualifies to file a Zantac cancer lawsuit? - **Ranitidine use:** branded Zantac or generic, for a meaningful period — most attorneys look for several months; some accept as little as 30 days. - **Cancer diagnosis:** one of the qualifying types (bladder, stomach, liver, esophageal, pancreatic, colorectal). - **Temporal relationship:** ranitidine use preceded the cancer diagnosis. - **No disqualifying factors:** some firms screen out heavy smoking (bladder claims) or chronic heavy alcohol use (liver claims), case by case. ## Settlement ranges and case values No global settlement has been reached. Based on comparable mass tort settlements involving cancer-causing products: | Factor | Estimated range | Notes | |---|---|---| | Standard cancer claim | $50K – $250K | Moderate use, qualifying cancer | | Strong causation | $250K – $500K | Long-term use, no confounders | | Aggressive cancers | $500K+ | Fatal or stage IV diagnoses | | Wrongful death | $500K – multi-million | Fatal cancer, strong documentation | ## Key legal theories - **Strict product liability:** ranitidine is defective because it is inherently contaminated with a carcinogen — unreasonably dangerous due to its propensity to generate NDMA, regardless of negligence. - **Failure to warn:** what manufacturers knew about NDMA formation and when; internal documents from discovery are central. - **Negligence and fraud:** inadequate testing and quality control, failure to remove the product, and alleged knowing concealment from consumers and regulators — potentially supporting punitive damages. ## Statute of limitations The clock typically starts when the plaintiff knew or should have known their cancer may be related to ranitidine use. Given widespread recall coverage in 2019–2020, courts may find many plaintiffs were on notice then, though the discovery rule can extend deadlines. Tolling arguments include fraudulent concealment, the continuing violation doctrine, and equitable tolling for minors or incapacitated individuals — evaluated jurisdiction by jurisdiction. ## Building a strong Zantac case Intake best practices: detailed questionnaires (usage history, diagnosis, treatment, confounders); verify diagnoses with pathology reports rather than self-reporting; document use through pharmacy or prescription records or credible declarations; screen SOL by jurisdiction and diagnosis date. Expert retention spans oncology, pharmacology, toxicology, and epidemiology for both general and specific causation — post-Daubert, methodologies must withstand either Daubert or Frye scrutiny depending on forum. ## Related mass tort litigation Attorneys in the Zantac space should monitor PFAS forever chemicals (https://www.masstortmarketingagency.com/mass-tort-leads/pfas), Camp Lejeune water contamination (https://www.masstortmarketingagency.com/mass-tort-leads/camp-lejeune), Roundup cancer litigation (https://www.masstortmarketingagency.com/mass-tort-leads/roundup), and the Ozempic litigation (https://www.masstortmarketingagency.com/mass-tort-leads/ozempic). Pre-qualified Zantac claimants: https://www.masstortmarketingagency.com/mass-tort-leads/zantac ## Frequently asked questions ### Is the Zantac lawsuit still active? Yes. The federal MDL 2924 effectively concluded after the Daubert ruling excluding plaintiffs' experts, but litigation continues actively in state courts. States with more permissive expert standards, such as California (Kelly/Frye), are the primary path forward. ### What cancers qualify for a Zantac lawsuit? Primarily bladder, stomach, liver, esophageal, pancreatic, and colorectal cancer. Some firms also accept kidney cancer, prostate cancer, and other types depending on the strength of the scientific evidence. ### How long do I have to file a Zantac lawsuit? Statutes of limitations vary by state, typically one to six years from diagnosis or discovery of the Zantac-cancer connection. With the FDA withdrawal in April 2020, many claimants may be approaching or past the deadline in some states — consult an attorney as soon as possible. ### How much are Zantac cancer cases worth? No global settlement exists. Values depend on cancer type, severity, treatment costs, duration of use, and jurisdiction — based on comparable litigation, roughly $50,000 to $500,000 or more for the most serious cases. ### Why was the federal Zantac MDL dismissed? It was not technically dismissed for all purposes, but Judge Rosenberg's Daubert ruling excluded plaintiffs' experts, making federal trials impossible without causation testimony. Activity shifted to state courts. ### Can I still file a new Zantac cancer claim? Potentially, yes — in state courts where the statute of limitations has not expired, including recent diagnoses of qualifying cancers after prior ranitidine use. An experienced mass tort attorney can evaluate each case. ### Who manufactured Zantac? Glaxo Holdings (now GSK, the original manufacturer), Sanofi (branded OTC Zantac), Boehringer Ingelheim, and Pfizer, plus numerous generic manufacturers. ### What did the FDA say about Zantac? The FDA ordered all ranitidine products withdrawn from the U.S. market on April 1, 2020, after determining NDMA levels increase over time and under normal storage conditions, posing an unacceptable risk to consumers. --- *Published by Mass Tort Agency. Canonical URL: https://www.masstortmarketingagency.com/blogs/zantac-cancer-lawsuit*